Kallyope
New York City, US · Founded 2014 · Delaware corporation · 55 employees on LinkedIn · 5 known investors
Kallyope is a biotechnology company founded by neuroscientists that discovers and develops novel therapeutics targeting neural networks, with a lead candidate in pivotal studies for acute migraine treatment and metabolism programs approaching clinical studies. It applies its integrated discovery platform to develop drugs for challenging diseases.
Also known as Kallyope Inc.
Founders & leadership
Kallyope was founded in 2014 by Tom Maniatis.
Board
Investors · 5
Reported raises · per SEC filings
Form D private placements$28.1M disclosed across 1 round · 2015
▶$28.1MraisedOct 2016 · 9 investors · BiotechnologyRule 506(b)
- William RieflinDirector
- Nancy ThornberryExecutive Officer, Director
- Terry McGuireDirector
- Kenneth ClarkExecutive Officer
- Tom ManiatisDirector
- Joshua WolfeDirector
- Tim KutzkeyDirector
- Offering amount
- $44M
- Amount sold
- $28.1M
- First sale
- Sep 2015
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Kallyope is a biotechnology company based in New York City that develops medicines derived from insights into neural signaling pathways. Its stated focus is the treatment of migraine, where it is advancing a late-stage program intended to provide an easy-to-use, first-in-class medication for acute treatment.
The company's lead asset, elismetrep, is being developed for the acute treatment of migraine and is in Phase 3 development. Kallyope positions itself as combining foundational neuroscience research with drug development execution, and it invites external collaborations through a partnering function.
Founding story
Kallyope was founded by neuroscientists whose research addressed previously unexplored neural networks; that work is described as being carried forward by a team of experienced drug developers.
Traction
Elismetrep, the company's lead asset for the acute treatment of migraine, has reached Phase 3 development.
▸Full profile — market position, technology, go-to-market, geography
Market position
Kallyope describes its late-stage migraine program as intended to deliver a first-in-class medication for acute treatment.
Technology
Kallyope's approach is based on insights into neural signaling pathways, which it applies to the discovery and development of medicines, currently directed at migraine.
Go-to-market
The company pursues collaborations with external partners to advance its programs, and maintains an active recruiting effort for its New York-based team.
The company targets patients with migraine, a condition it describes as affecting millions.
Geography
Kallyope is based in New York City.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Founder mafia
The Kallyope mafia →6 people who came through Kallyope went on to found or lead other companies.
Competitors · 2
by search overlap
Companies competing with Kallyope for the same Google search keywords, organic and paid, via search-intersection analysis.
Legal entities · 1
corporate structure▸Research sources · 1
primary sources listed
- Kallyopekallyope.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Kallyope do?
- Kallyope is a New York biotechnology company developing medicines based on neural signaling pathways, led by a Phase 3 migraine asset.
- Who founded Kallyope?
- Kallyope was founded by Tom Maniatis in 2014.
- Who are Kallyope's investors?
- Kallyope's investors include Dns Capital, Illumina Ventures, Lux Capital, The Column Group, Polaris Partners.
- How much funding has Kallyope raised?
- Kallyope has disclosed $28.1M raised across 1 round.
- Where is Kallyope headquartered?
- Kallyope is headquartered in New York City, US.